Capstone Asset Management’s Myriad Genetics MYGN Stock Holding History

Capstone Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$438K	Sell	16,968 -530	-3%	-$11.3K	0.01%	988
2017 Q1	$336K	Buy	+17,498	New	+$310K	0.01%	1181
2013 Q4	–	Sell	-10,714	Closed	-$252K	–	1934
2013 Q3	$252K	Sell	10,714 -210	-2%	-$5.97K	0.01%	1741
2013 Q2	$294K	Buy	+10,924	New	+$317K	0.01%	1585

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Capstone Asset Management's MYGN Position: Q2 2017 in Review

Capstone Asset Management reduced its Myriad Genetics (MYGN) stake by 3% in Q2 2017, selling an estimated $11.3K and leaving 16,968 shares worth $438K. The position accounts for 0.01% of the portfolio, ranked #988.

Capstone Asset Management first reported a position in MYGN in Q2 2013 and has held it in 4 quarters since. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Capstone Asset Management held 16,968 shares of Myriad Genetics worth $438K as of Q2 2017.
Capstone Asset Management sold 530 Myriad Genetics shares in Q2 2017, an estimated $11.3K.
Myriad Genetics made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #988 holding.
Capstone Asset Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 4 quarters since.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.